Former divisional head at German Centre for Infection Research (DZIF)
- Review of genetically engineered vaccine candidates, and key advantages over inactive and live attenuated
- DNA, recombinant and protein subunit vaccines and their potential in COVID-19
- Key advantages of mRNA vaccines and remaining hurdles in delivery, formulation and capacity constraints
- Case studies on Moderna (NASDAQ: MRNA) vs CureVac vs BioNTech (NASDAQ: BNTX)
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.